Antibodies

14 Dec 2018 Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
14 Dec 2018 Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints
14 Dec 2018 Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
13 Dec 2018 Novartis receives European Commission approval for self-administration of Xolair® across all indications
13 Dec 2018 New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
11 Dec 2018 Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
11 Dec 2018 Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015
11 Dec 2018 Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead
09 Dec 2018 Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-enhanced CD20 monoclonal antibody
09 Dec 2018 Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
09 Dec 2018 MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
07 Dec 2018 Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer
07 Dec 2018 FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
06 Dec 2018 Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
06 Dec 2018 Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
06 Dec 2018 GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
06 Dec 2018 Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
06 Dec 2018 Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted
06 Dec 2018 Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
05 Dec 2018 Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
05 Dec 2018 Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
05 Dec 2018 Celltrion Healthcare presents positive results for CT-P10, biosimilar rituximab, in advanced follicular lymphoma at the American Society of Hematology Meeting 2018
05 Dec 2018 Generon Presented Pre-Clinical Immunotherapy Results With CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format
05 Dec 2018 Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101
04 Dec 2018 aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top